A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
Crossref DOI link: https://doi.org/10.1007/s00280-017-3351-4
Published Online: 2017-06-20
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ueno, Makoto
Li, Chung Pin
Ikeda, Masafumi
Ishii, Hiroshi
Mizuno, Nobumasa
Yamaguchi, Taketo
Ioka, Tatsuya
Oh, Do Youn
Ichikawa, Wataru
Okusaka, Takuji
Matsuyama, Yutaka
Arai, Daichi
Chen, Li Tzong
Park, Young Suk
Furuse, Junji
License valid from 2017-06-20